ProMetic Life Sciences Inc. (PLI) PT Lowered to C$2.00
ProMetic Life Sciences Inc. (TSE:PLI) had its target price decreased by stock analysts at National Bank Financial from C$2.50 to C$2.00 in a research note issued to investors on Wednesday. The brokerage presently has a “sector perform” rating on the stock. National Bank Financial’s price target would indicate a potential upside of 52.67% from the stock’s previous close.
Several other research analysts have also issued reports on the stock. Royal Bank Of Canada lowered their price target on shares of ProMetic Life Sciences from C$4.00 to C$3.50 and set an “outperform” rating for the company in a report on Wednesday, August 16th. TD Securities lowered their price target on shares of ProMetic Life Sciences from C$4.50 to C$3.50 and set a “speculative buy” rating for the company in a report on Wednesday, August 16th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of C$3.50.
ProMetic Life Sciences (PLI) traded down C$0.01 during trading on Wednesday, reaching C$1.31. 272,829 shares of the company’s stock traded hands, compared to its average volume of 1,032,325. ProMetic Life Sciences has a 52-week low of C$1.12 and a 52-week high of C$2.92.
In other news, insider Bruce Pritchard sold 84,594 shares of ProMetic Life Sciences stock in a transaction on Friday, August 25th. The shares were sold at an average price of C$1.15, for a total value of C$97,283.10. Also, Director Dwun-Hou Chen sold 32,321 shares of ProMetic Life Sciences stock in a transaction on Thursday, August 24th. The shares were sold at an average price of C$1.14, for a total transaction of C$36,845.94. In the last quarter, insiders bought 184,150 shares of company stock valued at $231,429 and sold 388,397 shares valued at $507,577.
About ProMetic Life Sciences
Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.
Receive News & Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.